Enbrel

Type: Product
Name: Enbrel
First reported 11 hours ago - Updated 8 hours ago - 1 reports

Why Amgen Stock Is A Long-Term Investment Opportunity

Summary Amgen has a top-quality pipeline that should sustain long-term growth. Amgen's restructuring plan will provide savings and will enable the company to focus on growth areas. Amgen is generating strong cash flows and returns value to its shareholders ... [Published Seeking Alpha - 11 hours ago]
First reported 11 hours ago - Updated 11 hours ago - 1 reports

Healthcare at Home must improve further, warns General Pharmaceutical Council

Further improvements are needed at an NHS contractor branded “unsafe” for failing to deliver medication to thousands of critically ill patients on time, the latest inspection by the pharmacy watchdog has found.In June the Bureau revealed that Healthcare ... [Published TBIJ - 11 hours ago]
First reported Aug 26 2014 - Updated Aug 26 2014 - 1 reports

Ixekizumab superior to etanercept in psoriasis trials

Ixekizumab (Eli Lilly) has demonstrated superiority to etanercept (Enbrel, Amgen) in phase 3 studies for the treatment of moderate-to-severe plaque psoriasis.In three studies, patients were assigned to receive ixekizumab (80 mg every two or four weeks, ... [Published Dermatology Times - Aug 26 2014]
First reported Aug 25 2014 - Updated Aug 25 2014 - 1 reports

Five things for pharma marketers to know: Monday, August 25

Share this article:Five things for pharma marketers to know: Monday August 25Roche is no longer looking to own Japanese drugmaker Chugai in full. Bloomberg reports that the Swiss company has decided not to scoop up the 38% of shares it does not already ... [Published Medical Marketing And Media - Aug 25 2014]
First reported Aug 25 2014 - Updated Aug 25 2014 - 1 reports

Psoriatic arthritis outcomes worse with smoking

Share this article:Worse patient-reported outcomes, shorter treatment adherence, and poorer response to treatment among smokers.Psoriatic arthritis biologic treatment outcomes worsened by smokingPatients with psoriatic arthritis (PsA) who smoke are less ... [Published The Clinical Advisor - Aug 25 2014]
First reported Aug 25 2014 - Updated Aug 25 2014 - 1 reports

Kindred study of canine pain drug misses endpoint

San Francisco-based Kindred Bioscience ($KIN) did not meet the primary endpoint during a trial of CereKin, its drug for canine osteoarthritis, based off studies for Amgen ($AMGN) and Pfizer's ($PFE) Enbrel. The study was randomized, double-blind and placebo-controlled ... [Published Fierce Biotech IT - Aug 25 2014]
First reported Aug 25 2014 - Updated Aug 25 2014 - 1 reports

5 Step Psoriasis Action Plan

(HealthNewsDigest.com) - For years, psoriasis was viewed as a vexing inflammatory skin condition, and treated accordingly, but a growing body of evidence now suggests that it is more than skin deep and needs to be addressed in a more global manner. August ... [Published HealthNewsDigest.com - Aug 25 2014]
First reported Aug 22 2014 - Updated Aug 22 2014 - 2 reports

Eli Lilly Uncovers Positive Data from Ixekizumab Studies

Eli Lilly and Company ( LLY ) announced encouraging top-line results from three pivotal studies under the phase III UNCOVER program (n=3,866) on ixekizumab. The candidate is being developed for the treatment of moderate-to-severe plaque psoriasis.Patients ... [Published Yahoo! Finance - Aug 22 2014]
First reported Aug 21 2014 - Updated Aug 22 2014 - 25 reports

Lilly's Ixekizumab proves superior in Phase 3 Psoriasis studies

Eli Lilly and Company's investigational medicine ixekizumab was statistically superior to etanercept and placebo on all skin clearance measures in Phase 3 studies, the company said in disclosing top-line results from its pivotal UNCOVER studies in moderate-to-severe ... [Published PBR - News - Aug 22 2014]
First reported Aug 22 2014 - Updated Aug 22 2014 - 1 reports

Concurrent treatment with a tumor necrosis factor-alpha inhibitor and veno-venous extracorporeal ...

Idiopathic pneumonia syndrome (IPS) is a fatal non-infectious respiratory complication that develops after hematopoietic stem cell transplantation (HSCT). Because of the poor prognosis of post-HSCT patients with IPS requiring mechanical ventilatory support, ... [Published 7thSpace - Aug 22 2014]
First reported Aug 21 2014 - Updated Aug 21 2014 - 1 reports

Daiichi Sankyo Starts Phase III Japan Trials With Enbrel Biosimilar

Related Biotechnology, Pharmaceutical and Healthcare NewsDaiichi Sankyo has begun Phase III trials in Japan with a biosimilar Enbrel (etanercept) for rheumatoid arthritis.Original Article: NEXT ARTICLE More From BioPortfolio on "Daiichi Sankyo Starts ... [Published BioPortfolio - Aug 21 2014]
First reported Aug 06 2014 - Updated Aug 06 2014 - 4 reports

Progress in the treatment of early-stage inflammatory joint disease

Label extension granted for Enbrel (etanercept) in the treatment of adult patients with severe nr-axSpA.6 August, 2014 02:27 PMPfizer has announced that the European Commission (EC) has granted a licence extension for Enbrel® (etanercept) in the treatment ... [Published Hospital Pharmacy Europe - Aug 06 2014]

Quotes

...Ruth March , Vice President, Personalized Healthcare & Biomarkers at AstraZeneca, said, "This partnership has the potential to deliver an unprecedented amount of clinical information from a single test. Illumina's technology will inform doctors about the molecular make-up of their patients' tumours, enabling them to match medicines to the drivers of disease." The full research reports on AstraZeneca are available to download free of charge at:
"These findings strongly call for clinical testing of relevant drugs in human NASH and its complications" said senior author Michael Karin, PhD, Distinguished Professor of Pharmacology in UC San Diego's Laboratory of Gene Regulation and Signal Transducti...
"The total cost of the CereKin program has been approximately $4 million, which represents less than 5% of our cash resources. With over $100 million in funds, we have ample capital for additional programs" Chin said in a statement
"Specialty medications are a demanding, but growing area of pharmacy," says Pharmacist Jack Coultry, Wegmans manager of managed care. "Health outcomes can be improved through close contact with the prescribing physician and additional counseling by the pharmacist. Adding this enhanced care model for those customers who need it is a natural next step for us."

More Content

All (247) | News (207) | Reports (0) | Blogs (37) | Audio/Video (0) | Fact Sheets (3) | Press Releases (0)
sort by: Date | Relevance
Why Amgen Stock Is A Long-Term Investment Oppor... [Published Seeking Alpha - 11 hours ago]
Healthcare at Home must improve further, warns ... [Published TBIJ - 11 hours ago]
OMBP: Omni Bio Executing On Development Plan [Published Yahoo! Finance - Aug 26 2014]
UCSD Medical School Creates New Mouse to Stimul... [Published La Jolla Patch - Aug 26 2014]
Collaborations, Upcoming Seminar, Clinical Tria... [Published Michigan Live - Aug 26 2014]
New mouse model points to therapy for liver dis... [Published Ecancer Medicalscience - Aug 26 2014]
Ixekizumab superior to etanercept in psoriasis ... [Published Dermatology Times - Aug 26 2014]
Five things for pharma marketers to know: Monda... [Published Medical Marketing And Media - Aug 25 2014]
Psoriatic arthritis outcomes worse with smoking [Published The Clinical Advisor - Aug 25 2014]
Kindred study of canine pain drug misses endpoint [Published Fierce Biotech IT - Aug 25 2014]
Wegmans offers specialty pharmacy services in a... [Published Individual.com - Aug 25 2014]
Trading range and strategy ideas in Big Pharma [Published Khaleej Times - Aug 25 2014]
Novel Antibody Obliterates Plaque Psoriasis [Published Hospi Medica - Aug 25 2014]
5 Step Psoriasis Action Plan [Published HealthNewsDigest.com - Aug 25 2014]
Eli Lilly Uncovers Positive Data from Ixekizuma... [Published Yahoo! Finance - Aug 22 2014]
Zacks Reaffirms “Neutral” Rating for Pfizer (PFE) [Published American Banking News - Aug 22 2014]
Infliximab caused DILI most frequently among TN... [Published Orthopedics Today - Aug 22 2014]
Psoriasis Drug Ixekizumab Superior to Etanercep... [Published PT Community - Aug 22 2014]
Biotech comeback [Published Insurance News Net - Aug 22 2014]
Lilly's Ixekizumab proves superior in Phase 3 P... [Published PBR - News - Aug 22 2014]
Eli Lilly Announces Successful Phase III Result... [Published Bidness Etc - Aug 22 2014]
Lilly’s ixekizumab shows superiority over etane... [Published Pharma Letter - Aug 22 2014]
Lilly's psoriasis candidate tops Enbrel in phas... [Published PMLive - Aug 22 2014]
Concurrent treatment with a tumor necrosis fact... [Published 7thSpace - Aug 22 2014]
Eli Lilly's ixekizumab superior to etanercept a... [Published PharmaBiz - Aug 22 2014]
Lilly takes on Amgen's Enbrel [Published Medical Marketing And Media - Aug 21 2014]
Lilly’s Ixekizumab Results More Than Skin Deep ... [Published BioPortfolio - Aug 21 2014]
Market Update: Amgen Inc (NASDAQ:AMGN) – Lilly ... [Published Jutia Group - Aug 21 2014]
Ixekizumab shows superiority to etanercept in p... [Published Orthopedics Today - Aug 21 2014]
Eli Lilly says psoriasis drug aced its late-pha... [Published Indianapolis Star - Aug 21 2014]
1 2 3 4 5 6 7 8 9
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Lilly's Ixekizumab proves superior in Phase 3 P... [Published PBR - News - Aug 22 2014]
Eli Lilly and Company's investigational medicine ixekizumab was statistically superior to etanercept and placebo on all skin clearance measures in Phase 3 studies, the company said in disclosing top-line results from its pivotal UNCOVER studies in moderate-to-severe ...
Lilly's Ixekizumab Superior to Etanercept and P... [Published PR Newswire: Health - Aug 21 2014]
INDIANAPOLIS, Aug. 21, 2014 /PRNewswire/ -- Ixekizumab met all primary and key secondary objectives across three pivotal studies of 3,866 patients, the largest Phase 3 moderate-to-severe plaque psoriasis program to dateIxekizumab was superior to etanercept ...
Biological Drugs Market Will Reach USD 2, 87,13... [Published PR.com Press Releases - Aug 19 2014]
New York, NY, August 19, 2014 --( PR.com )-- Persistence Market Research (http://www.persistencemarketresearch.com) Released New Market Report on "Global Market Study on Biological Drugs: North America to Witness Highest Growth by 2020” the global biological ...
Doctor Criticized For His Questionable 'Treatme... [Published Techdirt - Jul 26 2014]
Dr. Edward Tobinick was the subject of an LA Times article in 2013 -- I'd link to it, but it appears to have disappeared, though I don't know why -- which highlighted his (apparently now discontinued) practice of prescribing a particular drug, Enbrel, ...
Legal thuggery directed at Steve Novella and Sc... [Published ScienceBlogs : Combined Feed - Jul 23 2014]
If there’s one characteristic of supporters of dubious medicine, it’s that they hate criticism. Whereas your average skeptic might not like criticism—sensitivity to criticism being a human trait and all—science- and evidence-based criticism tends to ...
1 2 3 4 5 6 7 8
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.